# Axsome Therapeutics (AXSM) ROE: -207.5% in 2025

URL: https://funkfolio.com/stock/AXSM/roe

> Axsome Therapeutics (AXSM) return on equity (ROE) was -207.5% in fiscal 2025, up 296.3 points from fiscal 2024. Its median over 10 fiscal years is -148.5%.

---

## Axsome Therapeutics (AXSM) return on equity (ROE)

**Return on equity · fiscal 2025:** -207.5% year ended Dec 31, 2025

Axsome Therapeutics (AXSM) earned a return on equity of -207.5% in fiscal 2025 (the year ended December 31, 2025). That is 296.3 percentage points higher than the -503.8% of fiscal 2024. Figures as of 17 Nov 2026, 23:01 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Return on equity, fiscal 2025:** -207.5%
- **Change on fiscal 2024:** +296.3 pts
- **Highest on record:** -26.3% fiscal 2015
- **Lowest on record:** -3301.5% fiscal 2018
- **Fiscal years on record:** 11 2015–2025

Figures as of 17 Nov 2026, 23:01 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

### Axsome Therapeutics return on equity (ROE), in more detail

Across the 11 fiscal years on record (2015–2025), the highest was -26.3% in fiscal 2015 and the lowest -3301.5% in fiscal 2018. The fiscal 2025 figure is higher than in 30% of the 10 earlier fiscal years on record, whose median is -148.5%.

### Return on equity by fiscal year

### Axsome Therapeutics return on equity (ROE), year by year

Axsome Therapeutics (AXSM) return on equity (ROE) by fiscal year

| Fiscal year | Return on equity | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | -207.5% | 296.3 pts up | Dec 31, 2025 |
| 2024 | -503.8% | 378.5 pts down | Dec 31, 2024 |
| 2023 | -125.3% | 45.5 pts up | Dec 31, 2023 |
| 2022 | -170.8% | 663.4 pts up | Dec 31, 2022 |
| 2021 | -834.3% | 743.8 pts down | Dec 31, 2021 |
| 2020 | -90.4% | 52.2 pts down | Dec 31, 2020 |
| 2019 | -38.2% | 3263.3 pts up | Dec 31, 2019 |
| 2018 | -3301.5% | 3128.4 pts down | Dec 31, 2018 |
| 2017 | -173.1% | 47.0 pts down | Dec 31, 2017 |
| 2016 | -126.1% | 99.8 pts down | Dec 31, 2016 |
| 2015 | -26.3% | — | Dec 31, 2015 |

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

### How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

### Return on equity at health care companies of similar size

Return on equity of Axsome Therapeutics and comparable companies

| Company | Return on equity | Fiscal year |
| --- | --- | --- |
| [Immunovant IMVT](https://funkfolio.com/stock/IMVT/roe) | -59.3% | 2026 |
| Axsome Therapeutics AXSM | -207.5% | 2025 |
| [Chemed CHE](https://funkfolio.com/stock/CHE/roe) | 27.1% | 2025 |
| [Oruka Therapeutics ORKA](https://funkfolio.com/stock/ORKA/roe) | -22.3% | 2025 |
| [Arrowhead Pharmaceuticals ARWR](https://funkfolio.com/stock/ARWR/roe) | -1439.4% | 2026 |
| [MSA Safety MSA](https://funkfolio.com/stock/MSA/roe) | 20.4% | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Axsome Therapeutics, figure by figure

- [Axsome Therapeutics market cap](https://funkfolio.com/stock/AXSM/market-cap)
- [Axsome Therapeutics revenue](https://funkfolio.com/stock/AXSM/revenue)
- [Axsome Therapeutics earnings](https://funkfolio.com/stock/AXSM/earnings)
- [Axsome Therapeutics earnings per share (EPS)](https://funkfolio.com/stock/AXSM/eps)
- [Axsome Therapeutics P/E ratio](https://funkfolio.com/stock/AXSM/pe-ratio)
- [Axsome Therapeutics P/S ratio](https://funkfolio.com/stock/AXSM/ps-ratio)
- [Axsome Therapeutics P/B ratio](https://funkfolio.com/stock/AXSM/pb-ratio)
- [Axsome Therapeutics free cash flow](https://funkfolio.com/stock/AXSM/free-cash-flow)
- [Axsome Therapeutics operating margin](https://funkfolio.com/stock/AXSM/operating-margin)
- [Axsome Therapeutics dividend](https://funkfolio.com/stock/AXSM/dividend)
- [Axsome Therapeutics shares outstanding](https://funkfolio.com/stock/AXSM/shares-outstanding)
- [Axsome Therapeutics total debt](https://funkfolio.com/stock/AXSM/total-debt)
- [Axsome Therapeutics cash on hand](https://funkfolio.com/stock/AXSM/cash)
- [Axsome Therapeutics total assets](https://funkfolio.com/stock/AXSM/total-assets)
- [Axsome Therapeutics return on invested capital (ROIC)](https://funkfolio.com/stock/AXSM/roic)

[Axsome Therapeutics (AXSM) overview: price, valuation and scorecard](https://funkfolio.com/stock/AXSM) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Axsome Therapeutics return on equity (ROE): questions and answers

**What is Axsome Therapeutics's return on equity?**

Axsome Therapeutics (AXSM) earned a return on equity of -207.5% in fiscal 2025 (the year ended December 31, 2025). That is 296.3 percentage points higher than the -503.8% of fiscal 2024.

**Is Axsome Therapeutics's return on equity high or low compared with its own history?**

The fiscal 2025 figure is higher than in 30% of the 10 earlier fiscal years on record, whose median is -148.5%.

**What are the highest and lowest return on equity figures on record for Axsome Therapeutics?**

Across the 11 fiscal years on record (2015–2025), the highest was -26.3% in fiscal 2015 and the lowest -3301.5% in fiscal 2018.

**How is Axsome Therapeutics's return on equity calculated?**

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

### Learn: return on equity (ROE)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Return on invested capital (ROIC) vs ROE and ROA](https://funkfolio.com/learn/stocks/return-on-invested-capital)

  Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Axsome Therapeutics (AXSM) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/AXSM/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.
